このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Orthofix Medical マネジメント

マネジメント基準チェック /04

Orthofix Medical'sの CEO はMassimo Calafioreで、 Jan2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.003%を直接所有しており、その価値は$ 12.55K 。経営陣と取締役会の平均在任期間はそれぞれ0.9年と1.4年です。

主要情報

Massimo Calafiore

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.003%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	1.1yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Massimo Calafiore (52 yo)

less than a year

在職期間

Mr. Massimo Calafiore is President, CEO & Director of Orthofix Medical Inc. from January 8, 2024 and as Interim President of Global Spine from January 10, 2024. Mr. Massimo Calafiore was the Chief Executiv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kimberley Elting	President of Global Orthopedics	1.5yrs	US$3.55m	0.18% $ 916.1k
Geoffrey Gillespie	VP & Corporate Controller	3.2yrs	US$887.05k	0.0051% $ 25.4k
Massimo Calafiore	President	less than a year	データなし	0.0027% $ 13.2k
Julie Andrews	Chief Financial Officer	less than a year	データなし	データなし
Aviva McPherron	President of Global Operations & Quality	less than a year	データなし	データなし
Julie Dewey	Chief Investor Relations & Communications Officer	less than a year	データなし	データなし
Jill Mason	Interim Chief Ethics & Compliance Officer and VP of Corporate Counsel	no data	データなし	データなし
J. Cedron	Chief Legal Officer & Corporate Secretary	less than a year	データなし	データなし
Lucas Vitale	Chief People & Business Operations Officer	less than a year	データなし	0.32% $ 1.6m
Ehab Esmail	Senior Vice President of Global Quality	5.5yrs	データなし	データなし
Tyler Lipschultz	President of Global Biologics	1.5yrs	データなし	データなし
Beau Standish	President of Global Enabling Technologies	no data	データなし	データなし

0.5yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: OFIXの経営陣は経験豊富とはみなされません ( 0.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Massimo Calafiore	President	less than a year	データなし	0.0027% $ 13.2k
John Henneman	Independent Director	1.5yrs	US$355.42k	0.092% $ 456.2k
Alan Bazaar	Independent Director	less than a year	US$300.00k	0% $ 0
Jason Hannon	Independent Director	4.1yrs	US$376.25k	0.012% $ 60.7k
Charles Kummeth	Independent Director	less than a year	US$300.00k	0.040% $ 198.9k
Michael Finegan	Independent Chair of the Board	less than a year	US$300.00k	0% $ 0
Michael Paolucci	Independent Director	8.3yrs	US$376.25k	0.032% $ 160.0k
Shweta Maniar	Independent Director	1.5yrs	US$355.42k	0.015% $ 75.9k
Wayne Burris	Independent Director	1.1yrs	US$539.70k	0.017% $ 84.6k

1.1yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: OFIXの取締役会は経験豊富ではない ( 1.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Orthofix Medical マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer

Orthofix Medical Inc. Announces Board Resignation

Recent updates

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc. Announces FDA 510(K) Clearance for the Rodeo Telescopic Nail

Orthofix Medical Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 21% to US$21.80

Consensus EPS estimates upgraded to US$1.27 loss

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Orthofix Medical Inc. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Profitability

Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer

Orthofix Medical Inc. Announces Board Resignation

Orthofix Medical Inc. Appoints Lucas Vitale as Chief People and Business Operations Officer

Consensus EPS estimates fall by 12%

Full year 2023 earnings: EPS misses analyst expectations

Orthofix Medical Inc. Provides Earnings Guidance for the Year 2024

Orthofix Medical Inc. to Report Q4, 2023 Results on Mar 05, 2024

Orthofix Medical Inc. Names Massimo Calafiore as President and Member of the Board of Directors Effective Immediately

Orthofix Medical Inc. Appoints Julie Andrews as Chief Financial Officer

Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis

Orthofix Medical Inc. Announces Board Changes

Orthofix Medical Inc. Appoints Massimo Calafiore as Chief Executive Officer, Effective in Early 2024

Consensus EPS estimates upgraded to US$3.50 loss, revenue downgraded

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Orthofix Medical Inc. Announces Full Commercial Launch of the Waveform L Interbody System for Lateral Lumbar Fusion Procedures

Orthofix Medical Inc. to Report Q3, 2023 Results on Nov 08, 2023

Orthofix Medical Inc. Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for Use in Spine and Orthopedic Procedures

Orthofix Medical Inc. Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures

Independent Director recently bought US$101k worth of stock

Orthofix Medical Inc. Announces Management Appointments

Orthofix Medical Inc. Announces Management Changes

Price target decreased by 11% to US$29.00

Consensus EPS estimates fall by 12%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Orthofix Medical Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 12% to US$32.67

Orthofix Medical Inc. Introduces New Phantom and Tornado Hins for Truelok Ring Fixation Systems

Orthofix Medical Inc. Announces Changes to Board of Directors

Orthofix Medical Inc Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody

Orthofix Medical Inc. Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc with Other Clinical and Scientific Abstracts At the Isass Annual Meeting

President of Global Spine Business recently sold US$157k worth of stock

President of Global Spine Business notifies of intention to sell stock

Consensus EPS estimates fall by 81%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthofix Medical Inc. Revises Sales Guidance for the Year 2023

Consensus revenue estimates decrease by 18%

Full year 2022 earnings: EPS misses analyst expectations

High number of new directors

Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System

Orthofix Medical Inc. Provides Unaudited Preliminary Net Sales Results Fourth Quarter and Full Year Ended December 31, 2022

Orthofix Medical Inc. Announces CEO Changes

Orthofix Medical Inc. Announces Publication of Data Demonstrating the Clinical Benefits of Trinity Elite Cellular Bone Allograft in Lumbar Fusion Procedures

Two unknown private equity fund sponsors submitted a non-binding indication of interest to acquire Orthofix Medical Inc. (NasdaqGS:OFIX) for approximately $460 million.

Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

Price target decreased to US$33.67

High number of new directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Orthofix Medical Inc. Provides Financial Guidance for the Full Year 2022

Orthofix Medical (NASDAQ:OFIX) Is In A Good Position To Deliver On Growth Plans

Orthofix Medical Inc. to Report Q3, 2022 Results on Nov 03, 2022

Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.

Consensus forecasts updated

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.

Orthofix stock falls amid SeaSpine merger despite rise in prelim Q3 revenue

マネジメント基準チェック /04